ArticleGut2025

Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.

Sungho Bea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.